Brokerages expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to post $4.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for HTG Molecular Diagnostics’ earnings, with the highest sales estimate coming in at $4.80 million and the lowest estimate coming in at $4.70 million. HTG Molecular Diagnostics posted sales of $7.73 million during the same quarter last year, which suggests a negative year-over-year growth rate of 38.6%. The company is scheduled to announce its next earnings report on Thursday, March 5th.
According to Zacks, analysts expect that HTG Molecular Diagnostics will report full year sales of $19.20 million for the current financial year. For the next financial year, analysts expect that the business will report sales of $24.25 million, with estimates ranging from $24.00 million to $24.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. HTG Molecular Diagnostics had a negative return on equity of 88.60% and a negative net margin of 76.97%. The company had revenue of $5.41 million for the quarter, compared to analyst estimates of $5.63 million.
Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of HTG Molecular Diagnostics in a research note on Friday, October 18th. ValuEngine upgraded HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. Craig Hallum set a $3.00 price target on HTG Molecular Diagnostics and gave the company a “buy” rating in a research note on Friday, September 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of HTG Molecular Diagnostics in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $3.13.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HTGM. Perkins Capital Management Inc. boosted its holdings in shares of HTG Molecular Diagnostics by 297.1% during the 3rd quarter. Perkins Capital Management Inc. now owns 2,353,153 shares of the medical research company’s stock valued at $1,564,000 after acquiring an additional 1,760,533 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of HTG Molecular Diagnostics by 504.3% during the 2nd quarter. BlackRock Inc. now owns 405,837 shares of the medical research company’s stock valued at $673,000 after acquiring an additional 338,681 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of HTG Molecular Diagnostics by 20.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research company’s stock valued at $2,413,000 after acquiring an additional 242,497 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of HTG Molecular Diagnostics by 153.9% during the 2nd quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 23,351 shares in the last quarter. 38.94% of the stock is currently owned by institutional investors.
Shares of HTGM traded down $0.04 during midday trading on Monday, hitting $0.62. The company’s stock had a trading volume of 827,501 shares, compared to its average volume of 509,695. HTG Molecular Diagnostics has a one year low of $0.56 and a one year high of $3.24. The company’s fifty day simple moving average is $0.70 and its two-hundred day simple moving average is $0.89. The company has a quick ratio of 5.07, a current ratio of 5.21 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $35.79 million, a price-to-earnings ratio of -1.06 and a beta of 1.56.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Featured Story: What are different types of coverage ratios?
Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.